Engineers Gate Manager’s Fulcrum Therapeutics FULC Stock Holding History

Engineers Gate Manager’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$886K	Buy	242,000 +115,891	+92%	+$705K	0.01%	1167
2026 Q1	$967K	Buy	+126,109	New	+$1.17M	0.01%	1070
2025 Q2	–	Sell	-12,519	Closed	-$36.1K	–	2282
2025 Q1	$36.1K	Buy	+12,519	New	+$46K	﹤0.01%	2058
2024 Q4	–	Sell	-25,234	Closed	-$90.1K	–	2346
2024 Q3	$90.1K	Buy	25,234 +5,374	+27%	+$39.9K	﹤0.01%	1928
2024 Q2	$123K	Buy	+19,860	New	+$150K	﹤0.01%	1721
2023 Q2	–	Sell	-29,822	Closed	-$85K	–	1833
2023 Q1	$85K	Buy	+29,822	New	+$267K	﹤0.01%	1523
2022 Q3	–	Sell	-21,356	Closed	-$105K	–	1779
2022 Q2	$105K	Buy	+21,356	New	+$209K	﹤0.01%	1729
2021 Q3	–	Sell	-11,773	Closed	-$123K	–	1754
2021 Q2	$123K	Sell	11,773 -5,371	-31%	-$54.3K	0.01%	1475
2021 Q1	$202K	Sell	17,144 -2,667	-13%	-$33K	0.01%	1593
2020 Q4	$232K	Sell	19,811 -294	-1%	-$3.32K	0.01%	1440
2020 Q3	$159K	Buy	+20,105	New	+$242K	0.01%	1476

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Engineers Gate Manager's FULC Position: Q2 2026 in Review

Engineers Gate Manager increased its Fulcrum Therapeutics (FULC) stake by 92% in Q2 2026, buying an estimated $705K and bringing the position to 242,000 shares worth $886K. The position accounts for 0.01% of the portfolio, ranked #1167.

Engineers Gate Manager first reported a position in FULC in Q3 2020 and has held it in 11 quarters since. The position peaked at $967K in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Engineers Gate Manager held 242,000 shares of Fulcrum Therapeutics worth $886K as of Q2 2026.
Engineers Gate Manager bought 115,891 Fulcrum Therapeutics shares in Q2 2026, an estimated $705K.
Fulcrum Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1167 holding.
Engineers Gate Manager first reported a position in Fulcrum Therapeutics in Q3 2020 and has held it in 11 quarters since.
Engineers Gate Manager's Fulcrum Therapeutics position peaked at $967K in Q1 2026.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.